Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.

Le infezioni in medicina·2026
Same author

Individualized TB care for drug-susceptible pulmonary tuberculosis: clinical alternatives when HRZE is contraindicated or not tolerated.

Expert review of respiratory medicine·2026
Same author

Plasma central nervous system biomarkers in heavily treatment-experienced people with HIV in the PRESTIGIO registry.

AIDS (London, England)·2026
Same author

The Human Virome in Infectious Diseases: Insights from Chronic and Acute Infections Across Body Sites-A Narrative Review.

Microorganisms·2026
Same author

Case Report: Beyond conventional diagnostics: mNGS support in a complex immunocompromised patient diagnosis.

Frontiers in medicine·2026
Same author

Cognitive and fine motor performance in people above 65 years of age with and without HIV.

Scientific reports·2026
Same journal

The lung microbiome in hematopoietic stem cell transplantation: immune interactions, clinical consequences, and emerging interventions.

Respiratory medicine·2026
Same journal

GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis.

Respiratory medicine·2026
Same journal

The Hidden Burden of Overlap Syndrome: Sleep Quality and Functional Impairment in Chronic Obstructive Pulmonary Disease.

Respiratory medicine·2026
Same journal

Quantitative CT-Derived Extrapulmonary Body Composition and the Risk of Acute Exacerbations in COPD: A Prospective Cohort Study.

Respiratory medicine·2026
Same journal

Characteristics of Patients with Acute Respiratory Failure in Obesity Hypoventilation Syndrome in the Intensive Care Unit: A Retrospective Cohort Study.

Respiratory medicine·2026
Same journal

The Next Frontier: From Clinical Remission to Structural Remission-Rethinking Airway Remodeling in Asthma.

Respiratory medicine·2026
See all related articles

Related Experiment Videos

Treating Tuberculosis without Rifampicin: an Open Dilemma.

Andrea Calcagno1, Amina Zaffagnini2, Emanuele Pontali3

  • 1Department of Translational Medicine, University of Eastern Piedmont, Novara; Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin; StopTB Italia ODV, Milan.

Respiratory Medicine
|June 25, 2026
PubMed
Summary
This summary is machine-generated.

Treatment for rifampicin-resistant (RR) and multidrug-resistant (MDR) tuberculosis (TB) often uses standard regimens. However, alternative drugs can substitute rifampicin in specific cases of RR-TB or functional RR-TB (fRR-TB).

Keywords:
BPaLMallergydrug-to-drug interactionmoxifloxacinmycobacterium tuberculosisrifampicin mono-resistance

Related Experiment Videos

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Antimicrobial Resistance

Background:

  • Tuberculosis (TB) treatment guidelines by the World Health Organization (WHO) recommend similar regimens for rifampicin-monoresistant (RR) and multidrug-resistant (MDR) TB.
  • Rifampicin is a crucial first-line anti-TB drug, but its use can be limited due to patient allergy, intolerance, or drug-drug interactions, leading to functional rifampicin mono-resistance (fRR-TB).
  • There is uncertainty regarding the optimal treatment strategies for patients with RR-TB and fRR-TB.

Purpose of the Study:

  • To conduct a literature review on the epidemiology and diagnostic tools for RR-TB and fRR-TB.
  • To assess available treatment options and associated costs for managing RR-TB and fRR-TB.
  • To provide guidance on managing TB cases where rifampicin cannot be used.

Main Methods:

  • A narrative literature review was performed, searching English-language articles from 1960 to 2025.
  • Keywords used included "tuberculosis", "rifampicin", "mono-resistance", and "tuberculosis".
  • Bibliographies of selected articles were manually reviewed for additional relevant studies.

Main Results:

  • The review covered the role of rifampicin, epidemiology of RR-TB, diagnostic methods for rifampicin resistance, and evolving treatment guidelines.
  • Studies reporting non-standard treatment regimens for RR-TB or fRR-TB were analyzed.
  • Potential alternative treatment options, their advantages, and disadvantages were summarized, with a proposed management flowchart.

Conclusions:

  • WHO-recommended regimens for RR/MDR-TB remain the primary treatment approach.
  • Despite data heterogeneity, scenarios exist where rifampicin can be substituted with alternative drugs.
  • Alternative drugs can be added to first-line regimens for patients with RR-TB or fRR-TB.